SpyGlass Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
SGP$38.37+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Description |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 9, 2026). |
| 3.2 | Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 9, 2026). |
| 4.1 | Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 4.2 | Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain holders of its capital stock, dated as of May 30, 2025 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 16, 2026). |
| 10.1+ | Form of Director and Executive Officer Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 16, 2026). |
| 10.2+ | 2026 Equity Incentive Plan and related form agreements (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.3+ | 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.4+ | Amended and Restated 2019 Equity Incentive Plan, as amended, and related form agreements (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 16, 2026). |
| 10.5+ | Outside Director Compensation Policy (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.6+ | Employee Incentive Compensation Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.7+ | Confirmatory Employment Letter between the Registrant and Patrick Mooney (incorporated by reference to Exhibit 10.7 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.8+ | Confirmatory Employment Letter between the Registrant and James Dennewill (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.9+ | Confirmatory Employment Letter between the Registrant and Chetan Pujara (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.10+ | Confirmatory Employment Letter between the Registrant and Jean-Frederic Viret (incorporated by reference to Exhibit 10.10 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 10.11+* | Professional Services Agreement between the Registrant and University Physicians, Inc., d/b/a University of Colorado Medicine, dated February 21, 2019, including the amendments thereto. |
| 10.12+ | Change in Control and Severance Plan and related form participation agreement (incorporated by reference to Exhibit 10.12 to the Registrant’s Registration Statement on Form S-1/A filed with the SEC on January 29, 2026). |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| 32.1† | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2† | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover page Interactive Data File (embedded with the Inline XBRL document) |
*Filed herewith.
- Indicates management contract or compensatory plan.
† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of SpyGlass Pharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.